As a form of responsibility of the pharmaceutical industry in monitoring the safety aspects of the drugs produced and marketed, PT Boehringer Ingelheim Indonesia diseminate safety communication for healthcare professionals regarding post-marketing cases of drug-induced liver injury (DILI) in patients with idiopathic pulmonary fibrosis (IPF) treated with Ofev®. Majority of the hepatic events occurred within the first three months of Ofev® initiation. Therefore, transaminases and bilirubin levels should be investigated upon initiation of treatment, at regular intervals during the first three months of treatment and periodically thereafter or as clinically indicated. Please refer to the letter for details.
Download : DHPC Ofev_Severe liver injury.pdf